Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Am J Prev Med. 2015 Jul 14;49(5):726–737. doi: 10.1016/j.amepre.2015.04.033

Table 2.

Physiological Outcomes in Intervention (I, n=105) and Control Group (C, n=104)

Outcomes Baseline Month 3 Month 6 Month 9 Month 12
HbAlc, % (SE)
 Intervention 8.9 (0.2) 7.9 (0.2) 7.7 (0.1) 7.8 (0.1) 7.6 (0.1)
 Control 8.8 (0.2) 8.3 (0.2) 8.3 (0.2) 8.2 (0.1) 8.1 (0.1)
 Diff (I-C) 0.1 (0.3) −0.4 (0.2) 0.6 (0.2) ** 0.4 (0.2) * 0.5 (0.2) **
Changes from baseline, % (SE)
 Intervention - 1.0 (0.1) *** 1.2 (0.1) *** 1.1 (0.1) *** 1.3 (0.1) ***
 Control - 0.5 (0.1) *** 0.5 (0.1) *** 0.6 (0.1) *** 0.7 (0.1) ***
 Diff (I-C) - 0.5 (0.2) ** 0.7 (0.2) *** 0.6 (0.2) ** 0.6 (0.2) ***
HbA1c ≥ 0.5% reduction from baseline, n (%)
 Intervention 64 (61.0%) 69 (65.7%) 66 (62.9%) 69 (65.7%)
 Control 45 (43.3%) 40 (38.5%) 46 (44.2%) 50 (48.1%)
 Diff (I-C) 17.7% ** 27.2% *** 18.7% ** 17.6% **
Glucose, mg/dL (SE)
 Intervention 160.1 (6.3) 128.5 (4.5) 127.9 (4.6) 131.6 (4.7) 124.8 (4.3)
 Control group 158.3 (5.3) 143.5 (5.3) 151.9 (5.2) 148.9 (4.8) 147.1 (4.9)
 Diff (I-C) 1.8 (8.2) 15.0 (6.8) * 24.0 (6.9) *** 17.3 (6.7) ** 22.3 (6.6) ***
Changes from baseline, mg/dL (SE)
 Intervention - 31.6 (5.0) *** 32.1 (5.0) *** 28.5 (5.0) *** 35.2 (5.0) ***
 Control group - 14.8 (5.1) ** −6.3 (5.1) −9.4 (5.1) 11.1 (5.1) *
 Diff (I-C) - 16.8 (7.1) * 25.8 (7.1) *** 19.1 (7.1) ** 24.1 (7.1) **
Triglyceride, mg/dL (SE)
 Intervention 177.3 (11.2) 159.5 ( 9.8) 163.0 ( 9.9) 169.4 (10.1) 167.6 (10.3)
 Control group 180.6 (12.6) 174.9 (11.4) 178.9 (11.5) 172.1 (11.3) 174.7 (12.3)
 Diff (I-C) −3.3 (16.8) −15.4 (15.0) −16 (15.1) −2.7 (15.2) −7.1 (16.0)
Changes from baseline, mg/dL (SE)
 Intervention 17.8 ( *
8.8)
−14.3 ( 8.8) −7.9 (8.8) −9.7 ( 8.8)
 Control group −5.8 ( 8.8) −1.7 ( 8.8) −8.5 ( 8.8) −5.9 ( 8.8)
 Diff (I-C) −12.1
(12.4)
−12.6 (12.4) 0.6 (12.4) −3.8 (12.4)
Total Cholesterol, mg/dL (SE)
 Intervention 188.5 (4.2) 178.2 (3.9) 176.2 (3.7) 178.5 (3.8) 178.8 (3.7)
 Control group 201.1 (5.1) 190.7 (4.1) 190.6 (3.9) 188.4 (4.0) 193.6 (4.7)
 Diff (I-C) −12.6 (6.6) 12.5 (5.7) * 14.4 (5.4) ** −9.9 (5.5) 14.8 (6.0) *
Changes from baseline, mg/dL (SE)
 Intervention - 10.3 (3.3) *** 12.3 (3.3) *** 10.0 (3.3) ** 9.7 (3.3) **
 Control group - 10.4 (3.3) *** 10.5 (3.3) *** 12.7 (3.3) *** 7.5 (3.3) *
 Diff (I-C) - −0.1 (4.6) −1.8 (4.6) 2.7 (4.6) −2.2 (4.6)
HDL, mg/dL (SE)
 Intervention 49.8 (1.2) 49.8 (1.2) 49.6 (1.2) 48.9 (1.2) 49.0 (1.2)
 Control group 48.7 (1.1) 49.6 (1.2) 49.5 (1.6) 52.1 (3.8) 49.7 (1.2)
 Diff (I-C) 1.1 (1.5) 0.2 (1.7) 0.1 (2.0) −3.2 (3.9) −0.7 (1.7)
Changes from baseline, mg/dL (SE)
 Intervention - 0.0 (1.7) −0.2 (1.7) −0.9 (1.7) −0.8 (1.7)
 Control group - 0.9 (1.7) 0.8 (1.7) 3.5 (1.7) * 1.1 (1.7)
 Diff (I-C) - −0.9 (2.4) −1.0 (2.4) −4.4 (2.4) −1.9 (2.4)
LDL, mg/dL (SE)
 Intervention 104.6 (3.3) 97.7 (3.0) 94.8 (2.9) 96.3 (3.0) 97.6 (3.1)
 Control group 115.6 (4.0) 107.4 (3.5) 107.6 (3.3) 105.2 (3.4) 109.1 (3.5)
 Diff (I-C) 11.0 (5.2)** 9.7 (4.6) * 12.8 (4.3) ** 8.9 (4.5) * 11.5 (4.6) *
Changes from baseline, mg/dL (SE)
 Intervention - 6.9 (2.8) ** 9.8 (2.8) *** 8.3 (2.8) ** 7.0 (2.8) *
 Control group - 8.2 (2.8) ** 8.0 (2.8) ** 10.4 (2.8) *** 6.5 (2.8) *
 Diff (I-C) - 1.3 (3.9) −1.8 (3.9) 2.1 (3.9) −0.5 (3.9)
Systolic BP, mg/dL (SE)
 Intervention 134.7 (1.8) 133.1 (1.8) 131.2 (1.8) na 134.3 (1.5)
 Control group 133.1 (2.0) 134.4 (2.0) 132.1 (1.7) na 136.2 (1.9)
 Diff (I-C) 1.6 (2.7) −1.3 (2.6) −0.9 (2.4) - −1.9 (2.4)
Diastolic BP, mg/dL (SE)
 Intervention 78.9 (1.0) 78.8 (1.0) 77.5 (0.9) na 79.0 (0.9)
 Control group 78.5 (1.1) 80.3 (1.0) 79.5 (1.1) na 81.2 (0.9)
 Diff (I-C) 0.4 (1.5) * −1.5 (1.4) −2.0 (1.4) - −2.2 (1.2)
BP controlled (Systolic/Diastolic BP<130/80), n (%)
 Intervention 37 (35.2%) 37 (35.2%) 40 (38.1%) na 31 (29.5%)
 Control group 38 (36.5%) 34 (32.7%) 38 (36.5%) na 25 (24.0%)
 Diff (I-C) −1.3% 2.5% 2.6% - 5.5%

Note: Boldface indicates statistical significance (*p<0.05, **p<0.01, ***p<0.001). na, not measured